NCT06465420View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A Vaccine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

October 15, 2024

Study Completion Date

September 15, 2025

Conditions
Haemophilus Influenzae MeningitisInvasive Haemophilus Influenzae Disease
Interventions
BIOLOGICAL

Haemophilus influenzae type a (Hia) glycoconjugate vaccine

0.5 mL intramuscular injection, given on days 0 and 28

Trial Locations (2)

B3K 6R8

Canadian Center for Vaccinology (CCfV), Halifax

H9H 4Y6

McGill University Health Centre (MUHC) Vaccine Study Centre, Montreal

Sponsors
All Listed Sponsors
collaborator

Hia Consortium

UNKNOWN

lead

InventVacc Biologicals Inc.

INDUSTRY

NCT06465420 - A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A Vaccine | Biotech Hunter | Biotech Hunter